A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Dose Administration, and to Evaluate the Effect of Food After a Single Oral Dose Administration in Healthy Subjects

Trial Profile

A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Dose Administration, and to Evaluate the Effect of Food After a Single Oral Dose Administration in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs FP 025 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Foresee Pharmaceuticals
  • Most Recent Events

    • 26 Feb 2018 Planned End Date changed from 1 Nov 2017 to 1 Jul 2018.
    • 26 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
    • 04 Dec 2017 Status changed from active, no longer recruiting to completed, according to a Foresee Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top